SeaStar Medical Reports Q3 2025 Financial Progress

Seastar Medical Holding Corporation ( (ICU) ) has released its Q3 earnings. Here is a breakdown of the information Seastar Medical Holding Corporation presented to its investors.

SeaStar Medical Holding Corporation is a commercial-stage healthcare company focused on innovative treatments for critically ill patients, particularly in the realm of organ failure and acute kidney injury (AKI). The company is known for its QUELIMMUNE therapy, which is designed to treat ultra-rare pediatric AKI.

In its third-quarter report for 2025, SeaStar Medical highlighted significant progress in expanding its QUELIMMUNE therapy to new top-rated children’s hospitals, achieving positive survival outcomes, and strengthening its financial position with a $12.4 million capital raise. The company also made strides in its NEUTRALIZE-AKI pivotal trial for adults.

Key financial metrics showed an increase in net revenue to $0.2 million, up from $0.1 million the previous year, driven by sales of the QUELIMMUNE therapy. Despite a net loss of $3.5 million, the company reduced its loss compared to the previous year. SeaStar Medical also reported a decrease in research and development and general administrative expenses, reflecting cost management efforts.

Strategically, SeaStar Medical expanded its clinical trial sites for the NEUTRALIZE-AKI trial and initiated a new trial for patients with acute chronic systolic heart failure. The company aims to complete enrollment by the end of 2026, with a focus on adult AKI, a market significantly larger than the pediatric segment.

Looking ahead, SeaStar Medical remains focused on advancing its clinical trials and expanding its market presence. The management is optimistic about the potential of its therapies to transform treatment for critically ill patients, with ongoing efforts to secure regulatory approvals and optimize financial resources for future growth.